Companies
- Companies
- Company details
Aeterna Zentaris Inc
Out-licensing
Development of Novel Cytotoxic Conjugates: AN-152 Targeted Anti-Cancer Agent Advances into Clinical Development More
Elucidation of Novel Ghrelin Antagonists: Promising Agents in the Management of Obesity More
Orally Bioavailable LHRH Antagonistic Peptidomimetics: Treatment of Endometriosis, Uterus Myoma, BPH and Malignant Disorders such as Breast and Prostate Cancer More
Phase I Clinical Development of AEZS-130 (EP-1572): A Novel Peptidomimetic Growth Hormone Secretagogue More
Phase I Clinical Development of ZEN-012 as a Potent Inhibitor of in vivo Tumour Growth: A Tubulin and Topoisomerase II Inhibitor More
Phase II Clinical Development of D-63153 for the Treatment of Hormone-Dependent Prostate Cancer and BPH: Dose-Dependent Suppression of Testosterone More
Phase II Clinical Development of Perifosine in Prostate Cancer, NSCLC and Multiple Myeloma: An Oral AKT Inhibitor More
Phase III Clinical Development of Cetrorelix for the Treatment of BPH and Endometriosis More
Preclinical Development of AEZS-127 (Erucylphosphocholine (ErPC)): A Novel Perifosine Analogue for the Treatment of Cancer More
Preclinical Development of Highly Potent Inhibitors of PI3K and Erk1/2 as Novel Anti-Cancer Agents More
Preclinical Development of Novel Vaccines Against Prostate Cancer and Melanoma More
Related Reports
Market Research Reports provided by reports.iptechex.com
Oct 2010 - 25 pages - $250
Mar 2011 - 104 pages - $500
Oct 2011 - 193 pages - $500
Nov 2010 - 193 pages - $600
Feb 2011 - 38 pages - $125
May 2011 - 45 pages - $125
Nov 2010 - 377 pages - $750
Nov 2010 - 245 pages - $600
Jan 2011 - 24 pages - $1,000
Mar 2011 - 48 pages - $500
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us